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ABSTRACT
Effectively treating KRAS-driven tumors remains an unsolved challenge. The 
inhibition of downstream signaling effectors is a way of overcoming the issue of direct 
targeting of mutant KRAS, which has shown limited efficacy so far. Bromodomain 
and Extra-Terminal (BET) protein inhibition has displayed anti-tumor activity in a 
wide range of cancers, including KRAS-driven malignancies. Here, we preclinically 
evaluate the effect of BET inhibition making use of a new BET inhibitor, BAY 1238097, 
against Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer 
(NSCLC) models harboring RAS mutations both in vivo and in vitro. Our results 
demonstrate that BET inhibition displays significant therapeutic impact in genetic 
mouse models of KRAS-driven PDAC and NSCLC, reducing both tumor area and tumor 
grade. The same approach also causes a significant reduction in cell number of a panel 
of RAS-mutated human cancer cell lines (8 PDAC and 6 NSCLC). In this context, we 
demonstrate that while BET inhibition by BAY 1238097 decreases MYC expression in 
some cell lines, at least in PDAC cells its anti-tumorigenic effect is independent of MYC 
regulation. Together, these studies reinforce the use of BET inhibition and prompt 
the optimization of more efficient and less toxic BET inhibitors for the treatment of 
KRAS-driven malignancies, which are in urgent therapeutic need.
INTRODUCTION
Mutation in the KRAS oncogene is one of the most 
frequent events in human cancers. In Non-Small Cell 
Lung Cancer (NSCLC), the main lung cancer subtype that 
accounts for the highest number of cancer-related deaths, 
KRAS is mutated in 30% of the cases [1]. In Pancreatic 
Ductal Adenocarcinoma (PDAC), which presents the 
lowest survival rates among all cancers, 90% of the tumors 
harbor KRAS mutations [2]. Because of its high prevalence 
and relevance, KRAS has been extensively studied with 
the ultimate objective of finding a safe and effective 
therapeutic strategy for patients presenting KRAS-driven 
tumors. Despite the knowledge acquired over the past 
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years and the new therapeutic technologies, treating 
KRAS-mutated cancers still remains a major health issue.
Indeed, targeting KRAS has proven challenging at 
multiple levels and different strategies have been explored: 
inhibiting KRAS translation by interfering with its messenger 
RNA, impairing KRAS processing using farnesyltransferase 
inhibitors, directly targeting the KRAS protein by peptide 
inhibitors or instructing the immune system against 
mutant KRAS [3]. However, no clinical trial based on 
these approaches has so far demonstrated convincing anti-
tumorigenic activity [4, 5]. Others have adopted a different 
approach by targeting downstream RAS effectors such as 
mTOR, PI3K, Akt or MEK. Although trials are ongoing, 
these drugs have not proven to be effective against RAS-
driven cancers in patients thus far [6]. In this context, 
some groups have recently demonstrated the therapeutic 
potential of Bromodomain and Extra-terminal (BET) protein 
inhibition in NSCLC and PDAC preclinical models [7–12]. 
Bromodomains recognize the N-terminal acetylated lysines 
on histones and recruit chromatin-regulating factors on 
promoters and enhancers to control gene expression. The 
key role of BET bromodomains in cancer initiation and 
maintenance has been highlighted by the development of 
small molecule BET bromodomain inhibitors [13]. Such 
inhibitors prevent the interaction between bromodomains and 
acetylated lysines, displaying significant anti-tumorigenic 
activity by regulating key engines of tumorigenesis like MYC 
[14, 15]. While the efficacy of BET inhibitors expands to a 
wide range of cancers, evidences of de novo and acquired 
resistance to some compounds have already been observed 
[16–18]. Moreover, there is an increasing concern about the 
potential toxicity that BET inhibitors might display in normal 
tissues versus cancer cells [19].
BAY 1238097 is a new BET bromodomain inhibitor 
with potent anti-tumor activity in B cell lymphoma and 
melanoma models, both in vitro and in vivo [20, 21], which 
has recently been evaluated in a phase I dose-escalation trial 
in patients with advanced malignancies [22]. In the present 
study, we have determined the anti-tumorigenic impact of 
BET inhibition against two different immunocompetent 
KRAS-driven mouse models. We have then expanded the 
study to human PDAC and NSCLC cell lines, to investigate 
whether the anti-tumorigenic activity of the compound is 
dependent on MYC downregulation in a human setting. Our 
results indicate that BET bromodomain inhibition might 
be an effective therapeutic option for patients harboring 
KRAS-mutated PDAC and NSCLC, even independently of 
MYC regulation, as seems to be the case in PDAC.
RESULTS
BET inhibition is effective against KRAS-driven 
NSCLC and PDAC mouse models
In order to preclinically assess the in vivo 
efficacy of BET inhibition by BAY 1238097 in an 
immunocompetent context, we made use of two well-
characterized KRAS-driven genetically engineered mouse 
models of PDAC (LSL-KrasG12D;Pdx1-Cre;p53ER/ER) 
and NSCLC (LSL-KrasG12D;p53ER/ER) [23, 24]. In both 
models, the constitutively-active KrasG12D mutant allele 
is expressed from the endogenous Kras locus after CRE-
mediated recombination. Briefly, constitutive KrasG12D 
transcription is prevented by a loxP-STOP-loxP (LSL) 
cassette. Expression of CRE recombinase excises the 
LSL cassette, activating the expression of KrasG12D and 
consequently triggering tumorigenesis in a tissue-specific 
manner. In the PDAC model, Cre recombinase is placed 
under the control of the Pdx1 promoter, which is activated 
in progenitor cells of mouse pancreas [23], while in the 
NSCLC model, adenocarcinomas are generated focally 
in the lung epithelium by delivering CRE recombinase 
through intranasal instillation of adenoviruses (Ad-Cre) 
[24]. Additionally, in both mouse models, the p53 wild 
type alleles were substituted by an inactive form of P53 
(p53ER/ER), which accelerates tumor progression to better 
recapitulate the aggressiveness and heterogeneity of 
human tumors [25, 26].
To investigate the therapeutic impact of BET 
inhibition by BAY 1238097 in PDAC, we treated tumor-
bearing 8 week-old LSL-KrasG12D;Pdx1-Cre;p53ER/ER 
mice. The animals were treated for 4 weeks with 35 mg/
kg of BAY 1238097 (maximum tolerated dose in mice) or 
with vehicle via oral gavage (Figure 1A), pancreata were 
collected and tumor burden evaluated by hematoxylin 
and eosin (H&E) staining (Supplementary Figure 1A). 
Histology analysis revealed a dramatic reduction of 
the tumor area relative to whole tissue in the treated 
samples compared to the control counterparts (28±21% 
vs 64±31%) (Figure 1B). In addition, while the tumors 
of the control group were mainly graded as PDACs, in 
the treated cohort tumors of lower grades (PanIN2 and 
PanIN3) were prevalent over PDAC regions (Table 1A). 
During the course of the treatment, weight was recorded 
twice a week as a general read-out of animal health. All 
mice showed a progressive increase of weight for both 
treated and control groups, although control mice gained 
more weight compared to the treated ones (10.12±4.04% 
vs 5.45±4.39%, at the endpoint) (Supplementary Figure 
2A), indicative of mild drug toxicity.
In parallel, to assess the efficacy of BAY 1238097 
in NSCLC, lung tumors were induced in 8- to 10-week 
old LSL-KrasG12D;p53ER/ER mice by Ad-Cre administration. 
Tumors were allowed to develop for 10 weeks and then 
animals were treated with BAY 1238097 or vehicle for 
4 weeks (Figure 1C). At treatment endpoint, lung tissues 
were harvested and H&E-stained (Supplementary Figure 
1B). Quantification of tumor area showed an even 
more striking effect than in PDAC: both tumor burden 
relative to whole lung epithelium and tumor number 
were dramatically reduced by BET inhibitor treatment 
(7.72±4.17% vs 0.45±0.60% and an average of 10±3 
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vs 2±1 tumors per animal, in untreated versus treated 
animals respectively) (Figure 1D). Strikingly, the lungs 
of 3 out of 8 treated animals were completely tumor-
free and the remaining 5 presented atypical adenomatous 
hyperplasia, while all the untreated mice showed presence 
of multiple adenocarcinomas (Table 1B). However, while 
the weight of control mice remained stable during the 
treatment window, the treated counterparts displayed a 
clear decrease (gain of 2.90±3.05 vs loss of 5.97±3.45 at 
the endpoint) (Supplementary Figure 2B). In this case and 
in accordance with the protocol approved by our ethical 
committee, 3 out of 8 treated animals that experienced 
more than 10% weight-loss skipped the treatment until 
weight recovery. Notably, all mice recovered rapidly - in 
only one or two days - indicating that the mild toxicity 
of the compound is quickly reversible. However, in this 
context, it is worth noting that 2 of the 5 treated animals 
still harboring tumors at the end of the experiments had 
been subject to a “drug holiday” due to weight loss, 
indicating that continuous treatment with the compound 
might be potentially more effective. Nevertheless, mice 
given suboptimal (interrupted) treatment still presented 
a clear reduction in tumor burden when compared to 
untreated animals (0.77±0.91% vs 7.72±4.17%).
Although these results suggest that NSCLC 
responds more effectively than PDAC to the treatment 
with the BET inhibitor, this therapeutic strategy seems to 
be a good therapeutic option against both KRAS-mutated 
diseases.
BET inhibition downregulates MYC in the 
KRAS-driven PDAC and NSCLC mouse cells
BET bromodomain inhibition has been reported to 
be a potential strategy to inhibit MYC [14], a central node 
of tumorigenesis. The BET inhibitor JQ1 has shown an 
Figure 1: Treatment with BAY 1238097 reduces tumor burden in genetic mouse models of KRAS-driven PDAC and NSCLC. 
Timeline of the therapeutic intervention with BAY 1238097 in (A) PDAC and (C) NSCLC are represented. In the pancreas model, tumors were 
allowed to evolve for 8 weeks to reach the PDAC stage, while in the lung model tumors developed for 10 weeks to adenocarcinomas. Treatment 
was then administered for 4 weeks. Therapeutic impact of BAY 1238097 after 4 weeks of treatment in (B) PDAC and (D) NSCLC is shown. 
Representative images of H&E-stained sections from lungs and pancreas of each model in vehicle (upper panels) and BAY 1238097 treated 
samples (lower panels) are shown. Black arrows indicate tumorigenic tissue and green arrows indicate normal tissue. Graphs show quantification 
of tumor burden as the percentage of tumor area relative to the whole tissue (tumor+normal tissue). Means and standard deviations are represented. 
For statistical analysis of the data, two-tailed unpaired t-tests between groups were performed; p<0.0001 (****) and p=0.0002 (***).
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Table 1: Mice treated with BAY 1238097 presented lower tumor grades compared to untreated animals
A
PDAC model
Sample ID Group Grades Observed
PC-1 Vehicle PDAC
PC-2 Vehicle PDAC
PC-3 Vehicle PDAC
PC-4 Vehicle PDAC
PC-5 Vehicle PDAC
PC-6 Vehicle PanIN3, PDAC
PC-7 Vehicle PDAC
PC-8 Vehicle PDAC
PC-9 Vehicle PDAC
PC-10 Vehicle PDAC
PC-11 Vehicle PDAC
PT-1 Treated PanIN2, PanIN3, PDAC
PT-2 Treated PanIN2, PanIN3, PDAC
PT-3 Treated PanIN2, PanIN3, PDAC
PT-4 Treated PanIN2, PanIN3, PDAC
PT-5 Treated PanIN3, PDAC
PT-6 Treated PanIN2, PanIN3, PDAC
PT-7 Treated PanIN2, PanIN3, PDAC
PT-8 Treated PanIN3, PDAC
PT-9 Treated PanIN2, PanIN3, PDAC
PT-10 Treated PanIN2, PanIN3, PDAC
B
NSCLC model
Sample ID Group Grades Observed
LC-1 Vehicle Adenocarcinoma
LC-2 Vehicle Adenocarcinoma
LC-3 Vehicle Adenocarcinoma
LC-4 Vehicle Adenocarcinoma
LC-5 Vehicle Adenocarcinoma
LC-6 Vehicle Adenocarcinoma
LC-7 Vehicle Adenocarcinoma
LC-8 Vehicle Adenocarcinoma
LT-1 Treated -
LT-2 Treated AAH
(Continued )
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anti-tumorigenic effect by suppressing MYC expression in 
both PDAC [12] and NSCLC [9]. In contrast, others have 
shown that BET inhibition is able to abolish tumorigenesis 
independently of MYC regulation [7, 8].
To determine the potential regulation of MYC in 
murine PDAC and NSCLC tumors treated with BAY 
1238097, we generated two cell lines from each tumor 
type (PDAC: mPDAC 1.1 and mPDAC 1.2; NSCLC: 
MLT#1 and MLT#6) (Supplementary Figure 3) and 
treated them in vitro for 3 days with the compound. In 
these conditions, BAY 1238097 caused a reduction in cell 
number at the nanomolar range in both PDAC and NSCLC 
cell lines (Figure 2A–2B). Interestingly, similarly to their 
in vivo counterparts, the 2 NSCLC-derived cell lines 
showed a higher sensitivity to BAY 1238097 compared to 
the PDAC-derived cell lines (IC50 of 0.072 and 0.075 μM 
vs 0.236 and 0.150 μM respectively).
To check for MYC levels, protein extracts were 
obtained after 24 hours of treatment at 2 different 
concentrations of the compound (one corresponding 
to the average of all 4 IC50s, and the other one 10-fold 
higher). Western Blot analysis showed a dose-dependent 
decrease of MYC protein levels in all 4 cell lines (Figure 
2C), implying that BAY 1238097 is able to regulate MYC 
expression in these experimental models.
MYC downregulation correlates with increased 
sensitivity to BET inhibition in NSCLC but not 
in PDAC human cell lines
To determine whether the therapeutic effect of BAY 
1238097 extends also to human tumors, a panel of NSCLC 
(H23, A549, H1299, H460, HOP-62 and H441) and PDAC 
(NP18, PANC-1, PaCa3, MIA PaCa-2, HPAF-II, AsPC-
1, Capan-1 and CFPAC-1) human cell lines were treated 
with the compound. Of note, all these cell lines harbor 
different activating mutations in the KRAS oncogene, with 
the exception of H1299 that is NRAS mutated, and most of 
them mutations in p53 as well (Supplementary Table 1). 
Importantly, simultaneous LKB1 and KRAS mutations in lung 
adenocarcinoma cell lines were previously shown to prevent 
MYC downregulation and sensitivity in response to BET 
inhibition [9]. Thus, we included 3 LKB1-mutated cell lines 
in our NSCLC panel (A549, H23 and H460) (Supplementary 
Table 1 A). With this comprehensive experimental system, 
we investigated the sensitivity of each cell line to the BET 
inhibitor, treating cells with different concentrations of the 
compound (0.63, 1.25, 2.5, 5, 10, 20 μM) for 3 days. Even 
though all human cell lines responded to 10 μM of BAY 
1238097 displaying a reduction of at least 50% of cell density, 
various degrees of sensitivity were observed (Figure 3A–3B). 
Overall, NSCLC cell lines presented higher sensitivity than 
PDAC cell lines, as previously observed in the mouse models 
both in vivo and in vitro. Among PDAC and NSCLC cell 
lines, MIA PaCa-2 and H1299 showed the highest response 
respectively.
In order to establish whether there was any 
correlation between efficacy of the BET inhibitor and 
regulation of MYC protein levels, all cell lines were 
treated with 0.63 μM of the compound (the lowest 
concentration tested, which was effective against the most 
sensitive cell lines) and protein lysates were collected 
24 hours later for Western Blot analysis. Half of the 
analyzed cell lines (7 out of the 14: CFPAC-1, AsPC-1, 
PaCa3, HPAF-II, Capan-1, HOP-62, and H441) displayed 
a reduction of MYC to less than 50% compared to the 
untreated cell lines (Figure 3C–3D and Supplementary 
Figure 4).
Consistently with previously published data [9], 
while the cell lines harboring wild type LKB1 in the 
NSCLC panel (HOP-62, H1299 and H441) showed a clear 
reduction in MYC levels, the cell lines with the mutated 
tumor suppressor (A549, H460 and H23) did not show a 
comparable regulation.
Six cell lines of our PDAC panel (CFPAC-1, AsPC-
1, PANC-1, MIA PaCa-2, HPAF-II and Capan-1) are 
B
NSCLC model
Sample ID Group Grades Observed
LT-3 Treated -
LT-4 Treated AAH
LT-5 Treated AAH
LT-6 Treated -
LT-7 Treated AAH
LT-8 Treated AAH
(A) Presence of pancreatic intraepithelial lesions (PanIN) of grade 2 and 3 and PDACs were evaluated in the pancreata sections 
of the PDAC model (Supplementary Figure 1A). (B) In the NSCLC model (Supplementary Figure 1B), presence of atypical 
adenomatous hyperplasias (AAH), large adenomas and adenocarcinomas were evaluated. “-“ represents tumor-free sections.
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Figure 2: PDAC- and NSCLC-derived cell lines from the LSL-KrasG12D;Pdx1-Cre;p53ER/ER and LSL-KrasG12D;p53ER/
ER genetic mouse models showed IC50s within the nanomolar range and a dose-dependent MYC decrease in response 
to BAY 1238097. 2 cell lines derived from each model were treated with varying concentrations of BAY 1238097 for 3 days. Cell were 
then fixed, stained with crystal violet and absorbance was quantified. IC50s were determined for cells derived from the PDAC (A) and 
NSCLC (B) models. Means and standard deviations are indicated. (C) A representative Western Blot is shown of all 4 cell lines treated with 
0.13 and 1.3 μM of BAY 1238097 for 24 hours. Tubulin and Ponceau S are provided as loading controls.
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Figure 3: Human PDAC and NSCLC cell lines respond to BAY 1238097 and show variable MYC downregulation 
upon BET inhibition. Cell density (relative to untreated controls) of (A) NSCLC and (B) PDAC cell lines after 3 days of treatment at 
0.63, 1.25, 2.5, 5, 10 and 20 μM was calculated using crystal violet staining and quantification of absorbance. A two-tailed unpaired t-test 
was performed for statistical analysis of each concentration vs. the corresponding untreated control; all comparisons show statistically 
significant differences (p<0.0001). Western Blots of (C) NSCLC and (D) PDAC cell lines untreated (-) or treated (+) with 0.63 μM of BAY 
1238097 were probed to detect MYC (n=2). Ponceau S staining was used as protein loading control. The dotted line indicates separate blots. 
Quantification of MYC downregulation is represented in Supplementary Figure 4.
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present in the Catalogue of Somatic Mutations in Cancer 
(COSMIC) and appear to harbor wild type LKB1 alleles 
(Supplementary Table 1 B). In those cells, we observed 
reduction of MYC protein levels, with the notable 
exception of MIA PaCa-2 that, despite harboring wild type 
LKB1, did not show any significant MYC downregulation 
(Figure 3D and Supplementary Figure 4). The other 2 
PDAC cell lines, whose LKB1 status is not present in 
COSMIC, responded to the inhibitor with a moderate 
(NP18) or strong (PaCa3) reduction in MYC levels too.
Interestingly, within the NSCLC cell lines, LKB1-
wild type cells that show a clear decrease of MYC protein 
upon BAY 1238097 treatment also display a significantly 
higher sensitivity to the inhibitor than the cell lines in 
which MYC levels remain unchanged or slightly decreased 
(Figure 4A). However, a similar analysis shows that this 
correlation is not true in PDAC cells, where the sensitivity 
to the inhibitor does not mirror MYC downregulation 
(Figure 4B).
In summary, in our study, BET inhibition by BAY 
1238097 showed remarkable efficacy against NSCLC 
and PDAC in vivo, significantly reducing tumor burden 
in genetic mouse models of KRAS-driven tumors. The 
BET inhibitor also showed efficacy in vitro in RAS-
mutated NSCLC and PDAC human cell lines. The degree 
of response partially correlated with a downregulation of 
MYC in NSCLC, but not in PDAC, implying the existence 
of other molecular effectors that will need to be further 
investigated. Taken together, these results demonstrate 
that BET bromodomain inhibition may be an effective 
anti-cancer approach against RAS-mutated PDAC and 
NSCLC, which are in urgent need of new therapeutic 
options.
DISCUSSION
In cancer generally, and particularly in PDAC and 
NSCLC, KRAS is one of the most frequently mutated 
oncogenes. Despite the increasing number of studies 
and the technological advance in the generation of more 
effective therapies, direct KRAS inhibition has proven to 
be extremely challenging and, when tested in the clinic, 
provided an insufficient therapeutic index in patients [5, 
27]. Hence, many groups have instead put their efforts 
into targeting Ras indirectly, through the inhibition 
of its multiple effector pathways. Among those, BET 
bromodomains might constitute a well characterized and 
tractable target. BAY 1238097 is a new BET inhibitor 
that has been tested against lymphoma [20] and, more 
recently, melanoma [21], but its use against KRAS-
mutated tumors has not been yet investigated. Here, we 
used genetic mouse models of KRAS-driven NSCLC and 
PDAC to underpin the efficacy of BET inhibitors against 
KRAS-driven malignancies and preclinically validate 
their use in tumors presenting mutations in KRAS. These 
models develop tissue-specific lesions that arise from a 
single alteration in KRAS and evolve, through acquisition 
of additional mutations, until the development of 
macroscopic adenocarcinomas, in a process that resembles 
the natural development of cancer in humans. Importantly, 
these experimental animals possess a fully operative 
immune system, a key element to evaluate the response to 
therapies, both in terms of efficacy and off-target toxicity. 
In addition, in order to enhance the tumor heterogeneity 
and genetic complexity, which constitute notable features 
of human cancers, we adopted models in which both 
endogenous copies of the p53 tumor suppressor have 
been substituted by an impaired p53 (p53ER/ER), allowing 
for accelerated mutational rate and the development of 
more aggressive and heterogeneous tumors [25, 26]. In 
both NSCLC and PDAC genetic mouse models, BAY 
1238097 caused a remarkable reduction of the tumor 
burden, not only decreasing the tumor area, but also 
reducing the tumor grade. Interestingly, the therapeutic 
impact was more dramatic in the NSCLC model than in 
PDAC, an observation that has been consistent across 
the subsequent in vitro studies both in mice and human 
cells. This suggests that an intrinsic feature of NSCLC 
cells might further sensitize them compared to PDAC 
cells. In addition, in vivo, the lower sensitivity of PDAC 
could also be related to the stromal fibro-inflammatory 
reaction characteristic of these tumors, which may result 
in lower drug penetration and, therefore, reduced efficacy, 
as previously reported for other drugs [28, 29].
Despite these slight differences, the overall efficacy 
of BET inhibition in these two models indicates that this 
can represent an effective therapeutic approach against 
both KRAS-mutated cancers.
The effectivity of BET bromodomain inhibitors, 
especially JQ1, has been linked to the downregulation of 
MYC [14, 15]. However, in some cases, BET inhibition 
may exert its anti-tumorigenic effect independently 
of MYC inhibition [30]. To investigate this aspect in 
a RAS-mutated context, we made use of both mouse-
derived and human cancer cell lines. BET inhibition 
does indeed downregulate MYC in most cells. However, 
MYC remained largely unchanged upon BAY 1238097 
treatment in a subset of 3 NSCLC cell lines. Notably, 
these are the only 3 cell lines presenting mutations in 
LKB1, which has been previously described to confer 
resistance to BET-mediated MYC inhibition [9]. Hence, 
even if LKB1 mutation does not confer resistance to BAY 
1238097, our results reinforce the correlation of wild type 
LKB1 and the susceptibility to MYC downregulation 
upon BET inhibition, which appears to predispose cells 
to a higher anti-tumorigenic effect compared to impaired 
MYC downregulation due to LKB1 mutations, at least in 
NSCLC. In PDAC, all the cell lines whose LKB1 status 
is known (6/8) harbor the wild type tumor suppressor and, 
consistently with the results in NSCLC, upon treatment 
with the BET inhibitor, downregulation of MYC is 
preponderant. However, the sensitivity of PDAC cell lines 
Oncotarget18742www.oncotarget.com
Figure 4: The higher response of NSCLC cell lines to BET inhibition correlates with MYC downregulation, while 
PDAC cells display MYC-independent sensitivity to the compound. Cell lines were grouped according to MYC downregulation 
upon BAY 1238097 treatment (refer to Supplementary Figure 4). In (A), A549, H460 and H23 display no change or a moderate MYC 
decrease (blue line), while HOP-62, H441 and H1299 show clear MYC downregulation (red line). In (B), PANC1, MIA PaCa-2 and NP18 
show minimum MYC changes (blue line), while CFPAC-1, AsPC-1, PaCa3, HPAF-II and Capan-1 display a clear reduction in MYC levels 
(red line). Means of the group of cell lines and standard errors of the mean (SEM) of these values are represented. For statistical analysis 
of the data, the area under the curve and SEM were calculated with GraphPad Prism 7 and two-tailed unpaired t-test between groups was 
performed; p = 0.0080 (**) and p=0.2173 (non-significant; n.s.).
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is lower than that of NSCLC cell lines, which implies that 
other molecular mechanisms besides MYC regulation 
might play a key role in mediating the anti-tumorigenic 
effect of BET inhibition. Indeed, in contrast to NSCLC, 
the degree of MYC regulation in our PDAC cell lines 
does not correlate with the response to the inhibitor. This 
phenomenon is best exemplified in MIA PaCa-2 and 
PaCa3: while MIAPaCa-2 cells barely display changes in 
MYC upon treatment, they show the strongest response to 
the compound; in contrast, PaCa3 cells, which display the 
most dramatic reduction in MYC levels upon treatment, 
are one of the least sensitive PDAC cell lines.
Therefore, our study suggests that the MYC-
mediated sensitivity of KRAS-mutated cancer cells to 
BET inhibition is highly context dependent and that such 
effectivity relies on more than one molecular mechanism. 
More investigation will need to be undertaken to identify 
the key molecular players, other than MYC, that contribute 
to the increased sensitivity to BET inhibitors.
Finally, it should be noted that, unfortunately, a 
recent Phase I clinical trial study based on BAY 1238097 
was discontinued due to dose-limiting toxicity in patients 
[22], indicating that more investigation is needed to 
explore and identify BET inhibitors with limited side 
effects that retain anti-tumor efficacy within an acceptable 
therapeutic window.
Other BET bromodomain inhibitors with different 
chemical scaffolds are currently being tested in the 
clinic for various haematological and solid tumor types, 
including pancreatic ductal adenocarcinoma and NSCLC. 
The most advanced ones include CPI-0610, GS-5829, 
GSK525762, INCB054329, INCB057643 and BMS-
986158, which are currently being evaluated in Phase I/
II or Phase II studies. It remains to be determined whether 
monotherapy with BET bromodomain inhibitors will 
show significant efficacy within an acceptable therapeutic 
window or whether combinations with other anti-cancer 
drugs will be required to increase the therapeutic impact 
of BET inhibitors [31, 32].
MATERIALS AND METHODS
BAY 1238097 preparation
Chemical structure and synthesis of BAY 1238097 
have been described [21]. Lyophilized BAY 1238097 
was stored at room temperature in a dry environment 
protected from light. Fresh working solutions (3.5g/L) 
were prepared weekly by stirring and resuspending the 
powder in 0.9% NaCl at 50ºC for 1 hour. HCl was added 
dropwise until a clear solution was obtained and pH was 
finally adjusted at 3.6. The resulting solution was filtered 
through a 0.22μm filter and stored at room temperature 
protected from light for a maximum of 7 days for animal 
studies or frozen at -20ºC for a maximum of 1 month for 
in vitro studies.
Animal studies
All the animal studies were performed in accordance 
with the ARRIVE guidelines and the 3 Rs rule of 
Replacement, Reduction and Refinement principles. 
Mice were maintained and treated following the protocols 
approved by the CEEA (Ethical Committee for the Use 
of Experimental Animals) at the Vall d’Hebron Institute 
of Oncology, Barcelona, Spain. To generate tumors in the 
NSCLC model, 8- to 10-week old LSL-KrasG12D;p53ER/ER  
mice were anesthetized with isoflurane (5%) and 30μL 
of EMEM + 12mM CaCl2 containing 5x10
7 pfu of Ad-
Cre were administered intranasally. Tumors in the 
PDAC model (LSL-KrasG12D;Pdx1-Cre;p53ER/ER) were 
spontaneously generated by tissue-specific expression of 
CRE recombinase. Mice of both models had a C56BL6/
FVBN mixed background. 8-week old and 10 weeks 
post-AdCRE infection, for PDAC and NSCLC models 
respectively, mice initiated the 4-week treatment. The 
animals were treated twice a week (first and fourth day) 
by oral gavage with BAY 1238097 (35mg/kg) or an 
equivalent volume of NaCl 0.9% (vehicle) for 4 weeks. 
Weights were measured before every treatment and, 
in case of 10% cumulative weight loss relative to the 
treatment onset, the regimen was interrupted until weight 
was recovered. After the 4-week treatment, the animals 
were euthanized with CO2. Either lungs or pancreata 
were collected, fixed in 4% paraformaldehyde (PFA) and 
paraffin-embedded for histological analysis.
Histology and sample analysis
Tissue sections were H&E-stained to quantify 
tumor burden (see Supplementary Figure 1). Accurate 
quantifications of tumor and normal tissue areas in the 
PDAC model were performed using 4 representative 
microscopy images of each section. In the NSCLC model, 
tumor and normal epithelium areas were quantified using 
the whole section. All areas were quantified using ImageJ. 
Percentage of tumor tissue was obtained by dividing the 
tumor area by the total area (tumor area + normal tissue 
area). Tumor grades of both models were blindly rated 
by a pathologist. Grades were evaluated considering 
previously published characterizations of both models 
[23, 24]. Representative images of each tumor grade are 
provided as Supplementary Figure 5.
Cell lines
H1299, H441 and A549 were purchased from ATCC. 
HOP-62 was purchased from NCI. H460 and H23 were 
kindly donated by Dr. Aniello Cerrato and all PDAC cells 
were a gift from Dr. Silvestre Vicent Cambra. Cell lines 
(with the exception of HPAF-II, NP18 and MIA PaCa-
2) were maintained in RPMI supplemented with 10% 
of FBS and 1% of glutamine. HPAF-II and NP18 were 
maintained in DMEM supplemented with 10% FBS and 
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1% of glutamine and MIA PaCa-2 with additional 2.5% 
horse serum. Murine cell lines were derived from the 
genetic mouse models of NSCLC (LSL-KrasG12D;p53ER/
ER) and PDAC (LSL-KrasG12D;Pdx1-Cre;p53ER/ER) when 
adenocarcinomas were fully developed and the presence of 
the KRAS(G12D) mutation was confirmed (Supplementary 
Figure 3). Murine cells were maintained in DMEM/F12 
containing 10% of FBS and 1% of glutamine.
In vitro efficacy studies
PDAC- and NSCLC-derived cell lines from the LSL-
KrasG12D;Pdx1-Cre;p53ER/ER and LSL-KrasG12D;p53ER/ER  
genetic mouse were seeded in 96-well plates at 500 cells/
well. After 24 hours, cells were treated with increasing 
concentrations of BAY 1238097: 0.008, 0.016, 0.031, 
0.063, 0.125, 0.250, 0.5, 1, 2 and 4 μM. 3 days after 
treatment, cells were fixed with PFA 4% for 20 minutes 
and stained with 0.5% crystal violet. Wells were washed 
twice using tap water and let dry for 24 hours. Staining 
was dissolved in 10% acetic acid and absorbance 
measured at 560nm to determine cell density. IC50s were 
determined using the XY Dose-response stimulation 
equation/log(dose) vs. response option of Graphpad Prism 
7. Human cancer cell lines were seeded in 96-well plate 
at 1.000 cells/well. Cell density (relative to untreated 
controls) after 3 days of treatment at 0.63, 1.25, 2.5, 5, 
10 and 20 μM was calculated using crystal violet staining 
and quantification of absorbance as previously described.
Western blot
For mouse cells, 5×105 cells were plated in 15cm 
dishes and treated after 24 hours with BAY 1238097 at 
0.13 and 1.3 μM. 24 hours later, cells were scraped and 
harvested using cold PBS. Cells were lysed by resuspending 
the pellets in RIPA buffer containing HaltTM Protease 
Inhibitor Cocktail (Thermo) followed by a 30-minute 
incubation at 4ºC and non-solubilized material was pelleted 
by centrifugation and discarded. Supernatants containing 
protein extracts were quantified by DCTM Protein Assay 
(Biorad) and equivalent protein concentrations dissolved 
in Laemmli buffer (containing 15% of β-mercaptoethanol). 
Samples were loaded in 15-well 10% Bis-Tris NuPAGE 
Novex Gels. The gel was run in MOPS buffer for 2 hours 
at 150V. Protein was transferred to a PVDF membrane 
using the standard procedure of the iBlot2 Dry Blotting 
System (Life Technologies). Membrane was stained using 
Ponceau to visualize total amount of protein as a loading 
control. Membrane was then blocked in 5% milk in PBS-
0.1%Tween. MYC was detected using the anti-MYC Y69 
antibody (Abcam) and tubulin using the anti-tubulin DM1A 
antibody (Sigma). Anti-rabbit and anti-mouse IgG-HRP (GE 
Healthcare) were used as secondary antibodies at 1:5,000. 
Membrane was incubated with Supersignal West Pico 
Chemiluminescent Substrate (Thermo) for 5 minutes before 
revealing. For human cell lines, each one was seeded at 
1×106 cells in 15cm dishes and, after 24 hours, either treated 
with 0.63 μM of BAY1238097 or left untreated. After 24 
hours of treatment, cells were harvested as previously 
described. The following procedure is equivalent to the 
one applied to the mouse cells. ImageJ quantification of the 
MYC bands normalized by total protein content (Ponceau 
staining) was calculated to quantify MYC downregulation 
(see Supplementary Figure 4).
Statistical analysis
All data were analyzed using GraphPad Prism 7.0 
software. Statistical analysis was performed by two-tailed 
unpaired Student’s t-test and results were considered 
significant when p<0.05. Results are shown as mean ±SD. 
When mean was calculated using means of different cell 
lines (see Figure 4), mean ±SEM was represented.
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